Case 1

Comparative renal effects of two lipid formulations of Amphotericin B, a retrospective, multicentre comparison of amphotericin B lipid complex (ABLC, Abelcet®) versus liposomal amphotericin B (AmBisome®)

Principal Investigators:

Barrie McTaggart, B. Sc. Pharm.

Hamilton Health Sciences Centre

Michael McKechnie, B. Sc. Pharm.,

Hamilton Health Sciences Centre

Co-investigators:

Luc Bergeron
Quebec City, Quebec

Anne-Marie Bombassaro
London Health Sciences Centre, London, Ontario

Marie-Chantale Bouwmeester
Maisonneuve-Rosemont Hospital, Montreal, Quebec

Sylvie Carle
McGill University Health Centre, Montreal, Quebec

Jeff Chan
Thunder Bay Regional Hospital, Thunder Bay, Ontario

Susan Fryters
Royal Alexandra Hospital, Edmonton, Alberta

Alfred Gin
Winnipeg Health Sciences Centre, Winnipeg, Manitoba

Anisha Lakhani
Surrey Memorial Hospital, Surrey, British Columbia

Monique Pitre
University Health Network, Toronto, Ontario

Kathryn Slater
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia

Objectives:

To compare the nephrotoxicity of ABLC and AmBisome in patients being treated for documented or suspected fungal infections at a number of Canadian institutions.

Status: Ongoing

Case 2

A pilot study to investigate the efficacy of bacitracin, gramicidin, polymyxin B (Polysporin) ointment (PO) for the eradication of methicillin-resistant Staphylococcus aureus

Principal Investigator:

Jeff Chan, B. Sc. Pharm.,
Thunder Bay Regional Hospital

Co-investigators:

Frank Edgson, MLT
Thunder Bay Regional Hospital

Pat Piaskowski, RN, HBScN, CIC
Thunder Bay Regional Hospital

Dr. Greg Gamble MD, MBA
Thunder Bay Regional Hospital

Sandra Stoger RN HBScN CCNC(c)
Thunder Bay Regional Hospital

Objectives:

The objective of this study is to investigate the efficacy of bacitracin, gramicidin, polymyxin B (Polysporin) ointment (PO) for the eradication of methicillin-resistant Staphylococcus aureus.

A secondary objective will to investigate whether the use of PO will result in sustained decolonization (³ 6 months).

Status: Ongoing

Case 3

Stability of dolestron in normal saline and 5% dextrose in water solutions stored at 4°C and 24°C in syringes.

Principal Investigator:

Scott E. Walker, M Sc Pharm,
Sunnybrook and Women's College Health Sciences Centre
Faculty of Pharmacy, University of Toronto.

Co-investigators:

Jeff Chan, B Sc Pharm
Thunder Bay Regional Hospital

Shirley Law, Dip Pharm Tech
Sunnybrook and Women's College Health Sciences Centre
Faculty of Pharmacy, University of Toronto.

Objectives:

In 1997, as a cost-cutting measure, a direct intravenous drug administration program was initiated. To facility this program we sought to determine the stability of a solution which was half the concentration (10 mg/mL) of the commercially available product (Anzemet®), which would be repackaged into 12.5 mL syringes using a validated, stability-indicating, liquid chromatographic method.

Status: Completed

:: back to top ::